跳至主要内容
临床试验/NCT05451147
NCT05451147已完成3 期

A Comparative Study of the Effect of "Chhinnavahni Kashaya Vati" Along With "Agnimantha Kwatha" & Metformin in the Management of Madhumeha w.s.r. to Diabetes Mellitus (Type II)

A & U Tibbia College Karol Bagh1 个研究点 分布在 1 个国家目标入组 48 人开始时间: 2018年9月3日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
48
试验地点
1
主要终点
OBJECTIVE PARAMETERS

研究概览

简要总结

Present study entitled "A Comparative Study of the Effect of "Chhinnavahni Kashaya Vati" along with "Agnimantha Kwatha" & Metformin in the management of Madhumeha w.s.r. to Diabetes mellitus (Type II)" is a small effort to find out an effective remedy for Madhumeha i.e. Diabetes Mellitus Type-2

详细描述

Single centered, randomized clinical trial of Chhinnavahni Kashaya Vati along with Agnimantha Kwatha was carried out on total of 60 registered patients. They were randomly classified in two groups, where in Group-A received Chhinnavahni Kashaya Vati with Agnimantha Kwatha and Group-B received Metformin for 12 weeks. Out of these, 12 patients did not complete the full course of the treatment.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Patients of either sex aged between 20 to 60 years.
  • If yes in any two of the four:
  • Blood sugar -fasting > 126 and ≤ 250 mg/dl.
  • PP > 200 mg/dl and ≤350 mg/dl.
  • Glycosylated Haemoglobin (HbA1c) > 6.5% and < 9%.
  • Subjects having classical symptoms of diabetes with random glucose levels ≥200mg/dl (≤350mg/dl).
  • Diagnosed cases of Type II Diabetics having Glycosylated Haemoglobin (HbA1c) between 6.5-9% without or {with metformin in a dose1g-1.5g/day (for Group-B)}.
  • Subjects who are able to come for follow up on fixed visits and are well aware about the treatment plan.
  • Subjects willing to participate and able to provide written informed consent.

排除标准

  • Age below 20 and above 60yrs.
  • Subject of Type-I DM (insulin dependent DM) or Type-II DM on insulin/OHA's other than metformin/ any other AYUSH medication for glucose control.
  • Subjects suffering from the complications of Diabetes mellitus viz., diabetic neuropathy, diabetic nephropathy, diabetic retinopathy etc. which require an urgent treatment.
  • Uncontrolled Hypertensive subjects (BP with or without medication >140/90 mmHg after 5 mins of rest).
  • Subjects with any unstable Heart disease or known cases of MI, unstable angina or CHF.
  • Patients with concurrent Hepatic Dysfunction (defined as AST and/or ALT > 2 times of the upper normal limit) or Renal Dysfunction, uncontrolled Pulmonary Dysfunction (asthmatic and COPD subjects).
  • Subjects with current or past diagnosis of malignancy (any malignancy diagnosis in last five years).
  • Subjects who have a recent history or who are currently known to abuse of alcohol or drugs.
  • Subjects suffering from major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Psycho-Neuro-Endocrinal disorders, TB, AIDS etc).
  • Female subject of child bearing potential who do not agree to remain abstinent or use medically acceptable methods of contraception during the study therapy and for 4 weeks after the end of study therapy.
  • Pregnant / Lactating women.
  • Subject on systemic or oral steroids, oral contraceptive pills or estrogen replacement therapy.
  • Subjects having hypersensitivity to any of the trial drug.
  • Subjects who have completed participation in any other clinical trial during the past six (06) months.

研究组 & 干预措施

Group A

Experimental

DRUG: Chhinnavahni Kashaya Vati FORM: Tablet DOSE: 1 g TDS (2 Tab. of 500 mg each), Before Meals MODE OF ADMINISTRATION: Oral ANUPAAN: 20 ml of Agnimantha Kwatha DURATION: 3 Months

干预措施: Chhinnavahni Kashaya Vati along with Agnimantha Kwatha (Drug)

GROUP B

Active Comparator

DRUG: Metformin FORM: Tablet DOSE: 500mg BID/TDS, Before Meals MODE OF ADMINISTRATION: Oral ANUPAAN:: Plain Water DURATION 3 Months

干预措施: Metformin Hydrochloride (Drug)

结局指标

主要结局

OBJECTIVE PARAMETERS

时间窗: Change from Baseline at End of trial [3 month]

Glycosylated Haemoglobin (HbA1c in %)

次要结局

  • SUBJECTIVE PARAMETERS(Change from Baseline at End of trial [3 month])

研究者

发起方
A & U Tibbia College Karol Bagh
申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr. Richa Bhardwaj

PG Scholar (Kayachikitsa)

A & U Tibbia College Karol Bagh

研究点 (1)

Loading locations...

相似试验